Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have been extended to include the treatment of adults with moderately active Crohn's disease, in addition to use in severe disease.

NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY
NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY

The TNF-alpha inhibitor should be used only when the response to conventional therapy, including a corticosteroid and/or an immunosuppressant, is inadequate or when such therapies are not tolerated or are contraindicated. 

View Humira drug record

Further information: AbbVie


Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

First body-identical combination HRT launched

First body-identical combination HRT launched

Bijuve is a combination of estradiol and progesterone,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...